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. . . the substantial
geographic varia-
tion demonstrated
for virtually all
medical services is a
bit embarrassing
and indicates that
we have yet to de-
fine the best ap-
proach to many
clinical conditions.n February 17, 2009, President Obama signed into law the American Re-
covery and Reinvestment Act. Of the $787 billion that was appropriated,
$150 billion was allotted for medical issues. Among the most controversial
rovisions of the medical spending was the allotment of $1.1 billion for comparative
ffectiveness research (CER). The definition given for CER is the rigorous evalua-
ion of the impact of different options that are available for treating a given medical
ondition for a particular set of patients. Many see this as a long overdue action that
ill salvage medicine by providing the data upon which optimal clinical care can be
ased. Others see it as a dangerous first step toward possible government control of
edical practice through reimbursement.
My first reaction upon learning of the CER program was to think, “What’s new?”
very day we grapple with choosing the diagnostic and therapeutic modalities that
ill be most effective for our patients. We pride ourselves on practicing evidence-
ased medicine. The importance of having data upon which to guide these manage-
ent decisions has long been well recognized. It seemed like the wheel was being
einvented.
The proponents of CER have marshaled considerable data to support the need for
heir proposal (1). Their arguments are set in the context of the progressive increase
n health care spending, which is currently nearly 16% of the gross domestic product
nd is projected to increase to 20% by 2016. First and foremost, they point to the
arked geographic variation in the application of medical procedures. Using heart
isease as an example, Wennberg et al. (2) reported a 4-fold difference in the num-
er of coronary artery bypass graft procedures in Medicare patients in different re-
ions of the country after correcting for appropriate variables. The frequency of by-
ass grafting was not correlated with the prevalence of myocardial infarction. The
ariation in medical practice resulted in a nearly 3-fold difference in spending be-
ween the lowest and highest spending regions, and expenditures are not consistently
elated to outcomes (3). Advocates stress that it is unknown which of the different
edical practices are superior, and that this is a stark demonstration of the need for
omparative effectiveness data.
Given the above issues, several questions occur: if it were easy to obtain such data,
hy is it that we neither already have them nor are in the process of getting them?
n addition, what kind of data would resolve these differences in regional practice?
hose proposing CER point out that acquiring approval for a new drug or proce-
ure from the Food and Drug Administration requires only the demonstration of
fficacy, not of superiority or even equivalence to alternate modalities. Major sup-
orters of medical research, such as the National Institutes of Health, often do not
ee comparative effectiveness as within their mission. Although industry provides
ajor sponsorship of clinical research, companies are often reluctant to place their
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ors. Thus, advocates maintain that this explains the
aucity of CER.
The type of research that would best yield compara-
ive effectiveness data is also uncertain. Obviously, pro-
pective randomized clinical trials, by eliminating or
inimizing confounding variables, would provide the
ighest quality data. However, such trials are very ex-
ensive and usually lengthy. In addition, as pointed out
n a prior Editor’s Page (4), they frequently include
nly a small percent of the affected population, often
xcluding patients with comorbidities that are prevalent
n clinical practice. Registry data can overcome these
imitations, but invariably introduce uncontrolled vari-
bles. The same can be said for meta-analysis (5).
hus, it seems apparent that the process of acquiring
ccurate high-quality comparative effectiveness data will
e neither easy nor inexpensive.
It seems to me that the difficulty in acquiring high-
uality data is one of the major problems with the
ER initiative. The clear cut, black versus white, clini-
ally important differences in effectiveness are often
bvious. As has been pointed out, you would not need
large clinical trial to establish the efficacy of para-
hutes for individuals jumping out of airplanes. Studies
or issues in the gray area often yield results showing
odest differences that may be subject to interpreta-
ion. While large clinical trials yield data applicable to
roups of patients, the results must be applied to indi-
idual patients with multiple variable characteristics. It
s and has always been the responsibility of the physi-
ian to apply these results to the individual patients
nder their care. While CER can provide guidance for
linical decisions, it is unrealistic and would be a mis-
ake to think that one size fits all and that any research
ould yield data applicable to every individual patient.
The major issue raised by those opposed to or with
erious concerns about CER is that it may represent
he first step toward an intrusive role for government
n the practice of medicine (6). Given the increasing
osts of health care, they question whether the major
oal of CER will actually be to control expenditures
ather than to increase quality. (Parenthetically, it is
ossible, of course, that CER data could result in in-
reased expenditures if costlier procedures proved more
ffective or if the manufacturers of drugs/devices shown
o be clearly superior increased their prices.) It is clear that for CER to change practice, and thereby possibly
educe costs, the data would have to be accepted and
cted upon by physicians and patients. Adherence to
he guidance provided by CER could be enhanced by a
arrot or a stick, that is, by providing incentives or
enalties that could most easily be applied through re-
mbursement policy. This could result in a powerful
ole for government in the practice of medicine. For
hose with the most drastic view, CER could be the
rst step to the rationing of health care.
My own view about CER is mixed. I certainly agree
hat the substantial geographic variation demonstrated
or virtually all medical services is a bit embarrassing
nd indicates that we have yet to define the best ap-
roach to many clinical conditions. It would be very
aluable to have data that defined which approach
ields superior effectiveness. Such research has almost
ertainly not received sufficient attention in the past.
evertheless, despite the new designation of “Compar-
tive Effectiveness Research,” and the enormous bolus
f money directed to the effort, the concept of defining
he most effective clinical practices and employing that
vidence in our clinical decisions is not new. In fact, it
s something that is woven into the fabric of daily clin-
cal practice. Much past and present clinical research
ddresses comparative efficacy. The Thrombolysis In
yocardial Infarction group alone has performed
early 40 studies in recent years dealing with clinical
ffectiveness. I also believe that the proponents may be
bit simplistic about the ease with which they will be
ble to provide definitive answers with CER. Clinical
esearch is difficult, expensive, and is best at providing
nswers for groups of patients rather than for individu-
ls. Finally, I think it is undeniable that cost consider-
tions are playing a role in the thrust for CER, and I
m a little uncomfortable that this could lead to an
nterposition of the government between the patient
nd physician. I do think that much of this can be
verted if the studies are done in an open and transpar-
nt fashion, involving the traditional research commu-
ity. Certainly, no one can be against cost-effective
edicine, and anything that enhances that goal would
e valuable. Although the new emphasis raises ques-
ions, on the balance, I think that CER is positive.
dditional data on comparative effectiveness should
elp us make better clinical decisions and result in bet-
er care for our patients.
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